Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes
- 31 August 2018
- journal article
- review article
- Published by Springer Nature in Current Diabetes Reports
- Vol. 18 (10) , 1-9
Abstract
Purpose of Review Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have positive effects on weight loss, blood pressure, hyperlipidemia, and glycemic control. They exhibit a broad range of effects on the cardiovascular system that are independent of changes in blood glucose. Cardiovascular outcome trials have demonstrated safety of GLP-1 RAs but results for cardiovascular efficacy were varied. The aim of the present review is the assessment of the effects of GLP-1 RAs on cardiovascular risk factors, and major cardiovascular events. Recent Findings Use of GLP-1 RAs was associated with relative risk reduction in cardiovascular mortality and all-cause mortality with no significant differences for the incidence of severe hypoglycemia, pancreatitis, pancreatic cancer, or medullary thyroid cancer when compared to placebo. Although there are differences between individual medications with respect to their effects on cardiovascular events, GLP-1 RAs offer a favorable risk-benefit profile. Summary The present review confirms the cardiovascular safety and efficacy vs placebo of GLP-1 RAs in patients with type 2 diabetes at moderate-to-high atherosclerotic cardiovascular risk without significant side effects. Although professional guidelines recommend metformin as the sole first-line agent, GLP-1 RAs can be used as first-line therapy in individuals with type 2 diabetes who either are intolerant to metformin or have high cardiovascular risk factors.Keywords
This publication has 62 references indexed in Scilit:
- Blood pressure‐lowering effects of GLP ‐1 receptor agonists exenatide and liraglutide: a meta‐analysis of clinical trialsDiabetes, Obesity and Metabolism, 2013
- Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysisBMJ Open, 2013
- Therapy in the Early Stage: IncretinsDiabetes Care, 2011
- Assessment of flow-mediated dilation in humans: a methodological and physiological guidelineAmerican Journal of Physiology-Heart and Circulatory Physiology, 2011
- Exenatide Affects Circulating Cardiovascular Risk Biomarkers Independently of Changes in Body CompositionDiabetes Care, 2010
- Switching to Once-Daily Liraglutide From Twice-Daily Exenatide Further Improves Glycemic Control in Patients With Type 2 Diabetes Using Oral AgentsDiabetes Care, 2010
- DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 WeeksDiabetes Care, 2010
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)The Lancet, 2009
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority studyThe Lancet, 2008
- Beneficial effects of once‐daily liraglutide, a human glucagon‐like peptide‐1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetesDiabetic Medicine, 2008